GSK
3 years ago ⋅ English ⋅ 10 min read
Newsroom
ViiV Healthcare announces new data at AIDS 2022 from unblinded phase of HPTN 084 study in women in sub Saharan Africa showing continued superior efficacy of injectable cabotegravir long-acting for PrEP over daily, oral TDF/FTC tablets

For media and investors only- No new HIV infections were observed in participants who initiated cabotegravir injections in the year following study unblinding- No birth defects reported... Read More
GSK
3 years ago ⋅ English ⋅ 2 min read
Newsroom
GSK signs agreement to support pandemic preparedness in Europe

For media and investors only- GSK will supply Adjupanrix to 12 participating European countries- The agreement is for the reservation of future production and supply of Adjupanrix in th... Read More
GSK
3 years ago ⋅ English ⋅ 5 min read
Newsroom
GSK delivers strong Q2 2022 sales of £6.9 billion +19% at AER, +13% at CER and Total EPS* from continuing operations** 17.5p -42% AER, -58% CER; Adjusted EPS of 34.7p +23% AER, +6% CER

GSK delivers strong Q2 2022 sales of £6.9 billion +19% at AER, +13% at CER and Total EPS* from continuing operations** 17.5p -42% AER, -58% CER; Adjusted EPS of 34.7p +23% AER, +6... Read More
GSK
3 years ago ⋅ English ⋅ 17 min read
Newsroom
ViiV Healthcare to present new data from innovative HIV treatment and prevention portfolio at AIDS 2022

Data to be presented include long-term and real-world data from portfolio of medicines, including long-acting and 2-drug regimensViiV Healthcare, the global specialist HIV company major... Read More
GSK
3 years ago ⋅ English ⋅ 2 min read
Newsroom
Board and Committee changes

For media and investors onlyGSK plc (LSE/NYSE: GSK) has today announced the following changes to its Board and Committees, which took effect immediately following the demerger of the Co... Read More
GSK
3 years ago ⋅ English ⋅ 5 min read
Newsroom
Completion of GSK Share Consolidation

GSK plc (LSE/NYSE: GSK) is pleased to announce that further to the Circular and Notice of General Meeting published by GSK on 1 June 2022, and following the announcements of 6 July 2022... Read More